EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy

Akanksha Singh, Anurag Singh, Rashmi Kushwaha, Shailendra Prasad Verma, Wahid Ali, Uma Shankar Singh

Annals of African Medicine · 2025

DOI: 10.4103/aam.aam_5_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of African Medicine, 2025. Verfasst von Akanksha Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Dasatinib, Transforming Growth Factor beta1, T-Lymphocytes, Regulatory, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-β1 at diagnosis and 3 months postdasatinib therapy. Materials and Methods: The Pathology and Clinical Haematology Departments at King George’s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-β1.

Results

T-regulatory cells, CTLA-4, and TGF-β1 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-β1 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders.

Conclusions

The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-β1 levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibTransforming Growth Factor beta1T-Lymphocytes, RegulatoryLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCTLA-4 AntigenProtein Kinase InhibitorsAntineoplastic AgentsHumansMaleFemaleAdultMiddle AgedProspective StudiesTreatment OutcomeYoung AdultCase-Control StudiesAgedFlow CytometryIndia

Stichwörter der Autor:innen

CTLA-4Cytotoxic T-lymphocyte-associated antigen 4cellules t-régulatricesdasatinibfacteur de croissance transformant β1inhibiteur de la tyrosine kinaset-regulatory cellstransforming growth factor-β1tyrosine kinase inhibitor

Substanzen

DasatinibTransforming Growth Factor beta1CTLA-4 AntigenProtein Kinase InhibitorsAntineoplastic AgentsCTLA4 protein, human

Autor:innen und Institutionen

  • Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India.
  • Department of Clinical Hematology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Zitieren

APA

Singh, A., Singh, A., Kushwaha, R., Verma, S. P., Ali, W., & Singh, U. S. (2025). Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy. Annals of African Medicine. https://doi.org/10.4103/aam.aam_5_24

Vancouver

Singh A, Singh A, Kushwaha R, Verma SP, Ali W, Singh US. Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy. Annals of African Medicine. 2025. doi:10.4103/aam.aam_5_24

BibTeX
@article{Singh2025,
  author = {Singh, Akanksha and Singh, Anurag and Kushwaha, Rashmi and Verma, Shailendra Prasad and Ali, Wahid and Singh, Uma Shankar},
  title = {Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy},
  journal = {Annals of African Medicine},
  year = {2025},
  doi = {10.4103/aam.aam_5_24}
}
Kostenlos starten →